Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.61 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5478998 | 0.80 | CYP19A1 (0.73) | CYP19A1TBXAS1CYP11B1CYP11B2AGTR2 | |
| SCHEMBL5481318 | 0.79 | HDAC1 (0.60) | CYP19A1ALDH1A1GAAMAPTHPGD | |
| SCHEMBL9853963 | 0.79 | CYP19A1 (0.80) | CYP19A1TBXAS1CYP11B1CYP11B2AGTR2 | |
| SCHEMBL24247782 | 0.78 | CYP19A1 (0.70) | CYP19A1TBXAS1CYP11B1CYP11B2AGTR2 | |
| SCHEMBL20646872 | 0.77 | CYP19A1 (0.68) | CYP19A1TBXAS1CYP11B1CYP11B2AGTR2 | |
| SCHEMBL4051000 | 0.75 | RXFP1 (0.56) | TBXAS1ALDH1A1GAAMAPTHPGD | |
| SCHEMBL4051003 | 0.75 | RXFP1 (0.56) | TBXAS1ALDH1A1GAAMAPTHPGD | |
| SCHEMBL5480229 | 0.75 | BCHE (0.62) | ALDH1A1GAAMAPTHPGDHTT | |
| SCHEMBL27993981 | 0.75 | CYP19A1 (0.65) | CYP19A1TBXAS1CYP11B1CYP11B2AGTR2 | |
| SCHEMBL5480128 | 0.74 | TBXAS1 (0.74) | CYP19A1TBXAS1CYP11B1CYP11B2ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | GRK3, NCOR1, GRM3 | CYP19A1 1511/4885TBXAS1 2364/4885CYP11B1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.